)
Visual
test
Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine (600276) investor relations material
Jiangsu Hengrui Medicine H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary25 Mar, 2026
Executive summary
Revenue reached RMB31,629.4 million in 2025, up 13.0% year-over-year, driven by innovative drug sales and licensing revenue.
Net profit attributable to shareholders was RMB7,711.1 million, a 21.7% increase year-over-year.
Innovative drug sales accounted for 58.3% of drug sales, with revenue from innovative drugs rising 26.1% year-over-year.
The company completed a dual listing in Hong Kong and closed five major overseas licensing deals.
Financial highlights
Gross profit increased 13.0% to RMB27,266.8 million; gross margin stable at 86.2%.
Net profit margin improved to 24.4% from 22.6% in 2024.
EBITDA (non-IFRS) rose 19.3% to RMB8,879.1 million.
R&D expenses were RMB6,961.2 million, 22.0% of revenue.
Final dividend proposed at RMB2.0 per ten shares.
Cash and bank balances at year-end were RMB40,854.7 million.
Outlook and guidance
Targeting over 30% growth in innovative drug sales in 2026.
Plans to launch approximately 53 innovative products and indications globally from 2026–2028.
Generic drug sales expected to decline as focus shifts to innovation.
Continued investment in R&D and global clinical trials to maximize pipeline value.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jiangsu Hengrui Medicine
- Net profit up 47%, revenue up 22.6% year-over-year, with strong innovation and global growth.600276
H2 202412 Dec 2025 - Net profit surged 29.67% on robust innovative drug sales and global licensing income.600276H1 202512 Dec 2025
- Q3 2025 saw double-digit revenue and profit growth, with strong cash flow and capital inflows.600276Q3 202527 Oct 2025
- Nine-month net profit jumped 32.98% on strong licensing income and robust revenue growth.600276Q3 202413 Jun 2025
- Net profit surged 48.67% on 21.78% revenue growth, led by innovative drugs and licensing income.600276H1 202413 Jun 2025
- Q1 profit surged on a one-time IDEAYA payment, while operating cash flow declined.600276Q1 20256 Jun 2025
Jiangsu Hengrui Medicine
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage